Bayer

Aveo’s tivozanib is knocked back by FDA once again

the TIVO-1 trial of VEGF inhibitor tivozanib – then partnered with Astellas – which compared the drug to Bayer’s VEGF drug Nexavar (sorafenib) in renal cell carcinoma (RCC).

New faces at Healthware Group and HRW

Commenting on her new role, Milburn said “from CVS and Sleepio to OneDrop and Bayer, to Happify and Sanofi, every day more and more strategic partnerships are being born between various

Roche eyes filings for Tecentriq/Avastin combo in liver cancer

plus anti-VEGF antibody Avastin (bevacizumab) or Bayer’s Nexavar (sorafenib), a standard first-line therapy for HCC.

Finalists

by AbbVie. with support from Lucid Group. Marketing Capability Development. by Bayer Russia.

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Novartis’ drug was the first VEGF inhibitor to reach the market for wet AMD but is facing the triple challenge of Bayer/Regeneron’s rival drug  Eylea (aflibercept) – now the market ... and Bayer adding another $2.1bn from other markets.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]